Disruptive treatments for acute, inflammatory diseases such as sepsis

Read More

CEO Mikael Lindstam participates in the Biotechgate Digital Partnering conference on 6-10 February

Read More

BioStock-artikel: Aptahem hoppas nå flera milstolpar under 2023

Read More

Aptamers

Aptamers are synthetic fragments of nucleic acid polymers which lack genetic information. They are the only known alternative to antibodies. Unlike antibodies, aptamers are synthetically produced, without any trace of endotoxin or other biological impurities as well as showing low immunogenicity.

Read More

Apta-1 in clinical phase

Disruptive in-house research showing the aptamer Apta-1’s uniqe multi-mechanistic profile. Apta-1 is currently in clinical phase 1 for the indication sepsis.

Read More

Investor Relations

Sepsis represents the highest healthcare costs of all critical conditions. In USA the yearly cost is estimated to 62 billion USD for the treatment and care of sepsis patients. Today there is no efficient treatment available.

Read More

About Aptahem and sepsis

Aptahem is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company’s lead candidate, Apta-1, is currently in early clinical phase with the main indication sepsis and other acute inflammatory conditions. This medical condition affects yearly 50 million people around the world and is lethal for more than 20-25% of these. Aptahem’s goal is to address the global medical need of treatments for sepsis and critical conditions associated with sepsis.

Today there is no treatment for sepsis or septic shock but only supporting treatment to maintain a healthy blood pressure and to improve oxygenation to prevent organ failure.

Video from Global Sepsis Alliance

Read More

Financial Calendar

  • Feb
    15
    2023

    Year-end Report 2022

  • Apr
    26
    2023

    Annual Report 2022

  • May
    11
    2023

    Interim Report Q1 2023

Presentations

Presentation and interview with CEO Mikael Lindstam

2022-11-24